# Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom

> **NCT03413579** · PHASE3 · COMPLETED · sponsor: **El Kendi Pharmaceuticals Manufacturing Company** · enrollment: 37 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** Nimotuzumab ( h-R3)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03413579
- **Lead sponsor:** El Kendi Pharmaceuticals Manufacturing Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2020-03
- **Final completion:** 2021-02
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03413579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03413579, "Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03413579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*